5080 RESULTS
Sort By:
RESEARCH NEWS 2019-02-20 Research News A decades-long study of more than 12,000 participants suggests that midlife inflammation drives cognitive decline in old age. Scientists led by Rebecca Gottesman, Johns Hopkins Medicine, Baltimore, report in the February 13 Neurology that ...
RESEARCH NEWS 2019-02-18 Research News Could a dietary supplement marketed directly to consumers moonlight as an effective treatment for ALS? It is within the realm of possibility, according to the results of a small Phase 1 pilot study testing EH301 in people with the disease. ...
RESEARCH NEWS 2019-02-15 Research News One of the characteristic features of Alzheimer’s disease is reduced blood flow in the brain. What brings it down? A paper in the February 11 Nature Neuroscience suggests that white blood cells can clog up the works. Scientists led by Chris ...
RESEARCH NEWS 2019-02-15 Research News Three studies published this week on the etiology of amyotrophic lateral sclerosis and frontotemporal dementia (ALS/FTD) spotlight a cell compartment that is often overlooked. They focus squarely on the nucleus, specifically the integrity of ...
RESEARCH NEWS 2019-02-15 Research News Malfunctioning mitochondria accumulate in the Alzheimer’s disease brain. Could they be purged? In the February 11 Nature Neuroscience, researchers led by Vilhelm Bohr at the National Institute on Aging, Baltimore, argue that these defective ...
RESEARCH NEWS 2019-02-08 Research News A damaged and leaky blood-brain barrier contributes to dementia, but just how has not been clear. Previous work implicated the clotting protein fibrinogen, which, when it penetrates the brain and coagulates, activates microglia and leads to ...
RESEARCH NEWS 2019-02-08 Research News Some studies of cerebrospinal fluid biomarkers suggest that women accumulate more tau pathology early in Alzheimer’s disease than do men. In the February 4 JAMA Neurology, researchers led by Rachel Buckley and Reisa Sperling at Massachusetts ...
RESEARCH NEWS 2019-02-07 Research News Yet another potential blood test for amyloid pathology has entered the ring. Using mass spectrometry to take an unbiased look at plasma proteins, researchers led by Abdul Hye, King’s College London, found a panel of biomarkers that predicted ...
RESEARCH NEWS 2019-02-07 Research News A cholesterol metabolite boosts accumulation of phosphorylated tau, according to a paper in the January 16 Cell Stem Cell. Researchers led by Lawrence Goldstein at the University of California, San Diego, reported that cholesteryl esters ...
RESEARCH NEWS 2019-02-05 Research News Three years ago in a high-profile paper, researchers led by Michal Schwartz at the Weizmann Institute of Science in Rehovot, Israel, deployed an immune-boosting approach pioneered for cancer in a mouse model of Alzheimer’s disease. The ...
RESEARCH NEWS 2019-02-04 Research News A paper published January 29 in Cell Reports claims that among the earliest changes in sporadic Alzheimer’s disease (SAD) are genetic changes that lead to premature neurogenesis. Scientists led by Bruce Yankner, Harvard Medical School, found ...
RESEARCH NEWS 2019-02-01 Research News This story was updated on February 5, 2019. Just when you thought ApoE biology couldn’t get any more complicated, scientists have discovered a new function for this apolipoprotein. According to a January 28 paper in Nature Medicine, ApoE ...
RESEARCH NEWS 2019-02-01 Research News Microgliosis goes hand-in-hand with Alzheimer’s disease, but the exact staging remains murky. A neuropathological study in the January 24 Nature Communications now places one type of microglial activation into the AD pathological cascade. ...
RESEARCH NEWS 2019-02-01 Research News St. Louis-based C2N announced this week that the Food and Drug Administration has fast-tracked review of its blood test for amyloid pathology, granting it Breakthrough Device designation. This status is reserved for devices that could ...
RESEARCH NEWS 2019-01-31 Research News Yesterday, Roche announced a halt to the Phase 3 CREAD 1 and CREAD 2 trials of the anti-amyloid antibody crenezumab. According to a company press release, an interim analysis found the trial was unlikely to reach its primary endpoint of ...
